Psychedeic-Chronicle-Logo

Suggestions

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS

Psychedeic-Chronicle-Logo

Psychedelic CEO Interviews

Mindset-Pharma-CEO-James-Lanthier-Exclusive-Interview-with-Psychedelic-Chronicle Psychedeic-Chronicle-Logo-White
Psychedelic CEO Interviews

Mindset Pharma CEO James Lanthier Exclusive Interview with Psychedelic Chronicle

August 31, 2022

At Psychedelic Chronicle our team not only delivers the latest news regarding the psychedelic industry ranging from medical research to industry analysis, but we also aim to provide comprehensive coverage of the many facets of this burgeoning field. This includes exclusive interviews and insights

Read More
Mindset-Pharma-CEO-James-Lanthier-Exclusive-Interview-with-Psychedelic-Chronicle Psychedeic-Chronicle-Logo-White
Psychedelic CEO Interviews

Mindset Pharma CEO James Lanthier Exclusive Interview with Psychedelic Chronicle

At Psychedelic Chronicle our team not only delivers the latest news regarding the psychedelic industry ranging from medical research to industry analysis,

August 31, 2022

Recent Posts

  • Choose Ketamine Complete Capital Raise to Expand Technology Platform
  • Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax
  • Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment
  • Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use
  • atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

Recent Comments

No comments to show.

Popular

Choose Ketamine Complete Seed Capital Raise to Expand Technology Platform

Choose Ketamine Complete Capital Raise to Expand Technology Platform

In a major milestone for mental health care, Austin-based Choose

Biomind Labs Secure Pre-IND Meeting, Seek FDA Feedback on New Triptax Depression Treatment

Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax

The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND)

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced

Psychedeic-Chronicle-Logo

© 2022 PSYCHEDELIC CHRONICLE
ALL RIGHTS RESERVED.

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS